Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1996 Dec;5(6):435–441. doi: 10.1155/S0962935196000609

Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and slL-6R) serum levels in systemic lupus erythematodes

E Robak 1, A Sysa-Jędrzejowska 1, T Robak 2,✉, H Stępień 3, A Woźniacka 1, E Waszczykowsk 1
PMCID: PMC2365820  PMID: 18475749

Abstract

We investigated a possible association between serum concentrations of tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α-Rp55 and sIL-6R) using an enzyme-linked immunosorbent assay (ELISA) in 55 patients with systemic lupus erythematodes (SLE) and 16 healthy controls. We also examined a possible association between the serum levels of these peptides and SLE activity, as well as TNF-α and IL-6 concentrations and the levels of their soluble receptors. The median concentrations of TNF-α, sTNF-α-Rp55 and IL-6 were significantly higher in SLE patients than in normal individuals. In contrast, there was no difference between the serum level of sIL-6R in both groups. We found positive correlations between the serum concentrations of TNF-α and IL-6 as well as their soluble receptors and disease activity. There were also correlations between TNF-α and sTNF-α-Rp55 as well as IL-6 and sIL-6R serum levels in SLE patients but there were no such correlations in the normal control group. In conclusion, an increase in the serum levels of TNF-α, sTNF-α-Rp55 and IL-6 may become useful markers for SLE activity. Patients with SLE have sIL-6R serum concentration similar to that as in normal individuals. However, it correlates with disease activity and the level of IL-6.

Full Text

The Full Text of this article is available as a PDF (644.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992 Feb 1;175(2):323–329. doi: 10.1084/jem.175.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aderka D., Englemann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed] [Google Scholar]
  3. Aderka D., Wysenbeek A., Engelmann H., Cope A. P., Brennan F., Molad Y., Hornik V., Levo Y., Maini R. N., Feldmann M. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 1993 Aug;36(8):1111–1120. doi: 10.1002/art.1780360812. [DOI] [PubMed] [Google Scholar]
  4. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996 Jun 27;334(26):1717–1725. doi: 10.1056/NEJM199606273342607. [DOI] [PubMed] [Google Scholar]
  5. Diez-Ruiz A., Tilz G. P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 1995 Jan;54(1):1–8. doi: 10.1111/j.1600-0609.1995.tb01618.x. [DOI] [PubMed] [Google Scholar]
  6. Engelberts I., Möller A., Schoen G. J., van der Linden C. J., Buurman W. A. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res. 1991 Apr;10(1-2):69–76. [PubMed] [Google Scholar]
  7. Gabay C., Roux-Lombard P., de Moerloose P., Dayer J. M., Vischer T., Guerne P. A. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol. 1993 May;20(5):815–821. [PubMed] [Google Scholar]
  8. Gaillard J. P., Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T., Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 1993 Apr;23(4):820–824. doi: 10.1002/eji.1830230408. [DOI] [PubMed] [Google Scholar]
  9. Gordon C., Emery P. Cytokines and the acute phase response in SLE. Lupus. 1993 Dec;2(6):345–347. doi: 10.1177/096120339300200601. [DOI] [PubMed] [Google Scholar]
  10. Handwerger B. S., Rus V., da Silva L., Via C. S. The role of cytokines in the immunopathogenesis of lupus. Springer Semin Immunopathol. 1994;16(2-3):153–180. doi: 10.1007/BF00197515. [DOI] [PubMed] [Google Scholar]
  11. Heaney M. L., Golde D. W. Soluble cytokine receptors. Blood. 1996 Feb 1;87(3):847–857. [PubMed] [Google Scholar]
  12. Heilig B., Fiehn C., Brockhaus M., Gallati H., Pezzutto A., Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol. 1993 Sep;13(5):321–328. doi: 10.1007/BF00920240. [DOI] [PubMed] [Google Scholar]
  13. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992 Apr 1;148(7):2175–2180. [PubMed] [Google Scholar]
  14. Horwitz D. A., Jacob C. O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol. 1994;16(2-3):181–200. doi: 10.1007/BF00197516. [DOI] [PubMed] [Google Scholar]
  15. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell. 1994 Jan 28;76(2):253–262. doi: 10.1016/0092-8674(94)90333-6. [DOI] [PubMed] [Google Scholar]
  16. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell. 1994 Jan 28;76(2):253–262. doi: 10.1016/0092-8674(94)90333-6. [DOI] [PubMed] [Google Scholar]
  17. Kitani A., Hara M., Hirose T., Harigai M., Suzuki K., Kawakami M., Kawaguchi Y., Hidaka T., Kawagoe M., Nakamura H. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992 Apr;88(1):75–83. doi: 10.1111/j.1365-2249.1992.tb03042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liang M. H., Socher S. A., Larson M. G., Schur P. H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 Sep;32(9):1107–1118. doi: 10.1002/anr.1780320909. [DOI] [PubMed] [Google Scholar]
  19. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992 Apr;63(1):10–12. doi: 10.1016/0090-1229(92)90084-2. [DOI] [PubMed] [Google Scholar]
  20. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992 Apr;63(1):10–12. doi: 10.1016/0090-1229(92)90084-2. [DOI] [PubMed] [Google Scholar]
  21. Maini R. N., Elliott M. J., Charles P. J., Feldmann M. Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol. 1994;16(2-3):327–336. doi: 10.1007/BF00197526. [DOI] [PubMed] [Google Scholar]
  22. Malavé I., Searles R. P., Montano J., Williams R. C., Jr Production of tumor necrosis factor/cachectin by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1989;89(4):355–361. doi: 10.1159/000234975. [DOI] [PubMed] [Google Scholar]
  23. Maury C. P., Teppo A. M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. 1989 Feb;32(2):146–150. doi: 10.1002/anr.1780320206. [DOI] [PubMed] [Google Scholar]
  24. Meijer C., Huysen V., Smeenk R. T., Swaak A. J. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 1993 Dec;2(6):359–365. doi: 10.1177/096120339300200605. [DOI] [PubMed] [Google Scholar]
  25. Metsärinne K. P., Nordström D. C., Konttinen Y. T., Teppo A. M., Fyhrquist F. Y. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int. 1992;12(3):93–96. doi: 10.1007/BF00290261. [DOI] [PubMed] [Google Scholar]
  26. Müllberg J., Oberthür W., Lottspeich F., Mehl E., Dittrich E., Graeve L., Heinrich P. C., Rose-John S. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994 May 15;152(10):4958–4968. [PubMed] [Google Scholar]
  27. Müllberg J., Schooltink H., Stoyan T., Günther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480. doi: 10.1002/eji.1830230226. [DOI] [PubMed] [Google Scholar]
  28. Nagafuchi H., Suzuki N., Mizushima Y., Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol. 1993 Dec 1;151(11):6525–6534. [PubMed] [Google Scholar]
  29. Samsonov M. Y., Tilz G. P., Egorova O., Reibnegger G., Balabanova R. M., Nassonov E. L., Nassonova V. A., Wachter H., Fuchs D. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus. 1995 Feb;4(1):29–32. doi: 10.1177/096120339500400107. [DOI] [PubMed] [Google Scholar]
  30. Spronk P. E., ter Borg E. J., Limburg P. C., Kallenberg C. G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992 Oct;90(1):106–110. doi: 10.1111/j.1365-2249.1992.tb05840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Swaak A. J., Nossent J. C., Smeenk R. J. Systemic lupus erythematosus. Int J Clin Lab Res. 1992;22(4):190–195. doi: 10.1007/BF02591422. [DOI] [PubMed] [Google Scholar]
  32. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  33. Tracey K. J. TNF and Mae West or: death from too much of a good thing. Lancet. 1995 Jan 14;345(8942):75–76. doi: 10.1016/s0140-6736(95)90055-1. [DOI] [PubMed] [Google Scholar]
  34. Van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yasukawa K., Futatsugi K., Saito T., Yawata H., Narazaki M., Suzuki H., Taga T., Kishimoto T. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol Lett. 1992 Feb;31(2):123–130. doi: 10.1016/0165-2478(92)90138-e. [DOI] [PubMed] [Google Scholar]
  36. ter Borg E. J., Horst G., Limburg P. C., Kallenberg C. G. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol. 1990 Oct;82(1):21–26. doi: 10.1111/j.1365-2249.1990.tb05398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES